XNASINMD
Market cap1.43bUSD
Dec 23, Last price
16.95USD
1D
-0.76%
1Q
1.80%
IPO
141.80%
Name
Inmode Ltd
Chart & Performance
P/E
7.25
P/S
2.91
EPS
2.34
Div Yield, %
0.00%
Shrs. gr., 5y
6.09%
Rev. gr., 5y
37.49%
Revenues
492m
+8.32%
Net income
198m
+22.54%
CFO
177m
-2.62%
Earnings
Feb 11, 2025
Profile
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 492,048 8.32% | 454,271 27.05% | 357,565 73.49% | |||||
Cost of revenue | 296,388 | 256,417 | 190,888 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | 195,660 | 197,854 | 166,677 | |||||
NOPBT Margin | 39.76% | 43.55% | 46.61% | |||||
Operating Taxes | 19,348 | 39,946 | 2,928 | |||||
Tax Rate | 9.89% | 20.19% | 1.76% | |||||
NOPAT | 176,312 | 157,908 | 163,749 | |||||
Net income | 197,919 22.54% | 161,520 -2.09% | 164,971 119.87% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 5,504 | (41,085) | (15,022) | |||||
BB yield | -0.29% | 1.35% | 0.25% | |||||
| Debt | ||||||||
Debt current | 2,404 | 1,453 | 1,209 | |||||
Long-term debt | 15,630 | 7,018 | 6,614 | |||||
Deferred revenue | 3,766 | 3,959 | 2,751 | |||||
Other long-term liabilities | 1,399 | 303 | 4,831 | |||||
Net debt | (724,271) | (539,512) | (408,691) | |||||
| Cash flow | ||||||||
Cash from operating activities | 176,826 | 181,578 | 174,885 | |||||
CAPEX | (705) | (1,575) | (939) | |||||
Cash from investing activities | (136,064) | (109,474) | (160,106) | |||||
Cash from financing activities | 5,504 | (41,085) | (15,022) | |||||
FCF | 142,939 | 145,777 | 155,397 | |||||
| Balance | ||||||||
Cash | 741,605 | 547,383 | 415,914 | |||||
Long term investments | 700 | 600 | 600 | |||||
Excess cash | 717,703 | 525,269 | 398,636 | |||||
Stockholders' equity | 691,992 | 488,255 | 332,907 | |||||
Invested Capital | 109,562 | 56,346 | 93,754 | |||||
ROIC | 212.54% | 210.40% | 178.36% | |||||
ROCE | 24.41% | 36.33% | 39.07% | |||||
| EV | ||||||||
Common stock shares outstanding | 85,954 | 85,404 | 86,017 | |||||
Price | 22.24 -37.70% | 35.70 -49.42% | 70.58 197.30% | |||||
Market cap | 1,911,608 -37.30% | 3,048,913 -49.78% | 6,071,094 203.78% | |||||
EV | 1,187,337 | 2,509,401 | 5,662,403 | |||||
EBITDA | 196,283 | 198,534 | 167,194 | |||||
EV/EBITDA | 6.05 | 12.64 | 33.87 | |||||
Interest | 3,612 | |||||||
Interest/NOPBT | 1.83% | |||||||